Use of Antiviral Agents and other Therapies for COVID-19

被引：3

作者：

Blaskovich, Mark A. T. ^{[1
,2
]}

Verderosa, Anthony D. ^{[1
]}

机构：

[1] Univ Queensland, Inst Mol Biosci, Ctr Superbug Solut, St Lucia, Qld, Australia

[2] Univ Queensland, Inst Mol Biosci, Ctr Superbug Solut, 306 Carmody Rd Bldg 80, St Lucia, Qld 4072, Australia

来源：

SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE | 2023年 / 44卷 / 01期

关键词：

COVID-19; SARS-CoV-2; antiviral; protease inhibitor; polymerase inhibitor; EPIDEMIC PREPAREDNESS; PROTEASE INHIBITOR; IVERMECTIN; HYDROXYCHLOROQUINE; CHLOROQUINE; ENTRY;

D O I：

10.1055/s-0042-1758837

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

The coronavirus disease 2019 (COVID-19) pandemic led to a remarkably rapid development of a range of effective prophylactic vaccines, including new technologies that had not previously been approved for human use. In contrast, the development of new small molecule antiviral therapeutics has taken years to produce the first approved drugs specifically targeting severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), with the intervening years filled with attempts to repurpose existing drugs and the development of biological therapeutics. This review will discuss the reasons behind this variation in timescale and provide a survey of the many new treatments that are progressing through the clinical pipeline.

引用

页码：118 / 129

页数：12

共 82 条

[1] Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial [J].

Ader, Florence ;

Bouscambert-Duchamp, Maude ;

Hites, Maya ;

Peiffer-Smadja, Nathan ;

Poissy, Julien ;

Belhadi, Drifa ;

Diallo, Alpha ;

Le, Minh-Patrick ;

Peytavin, Gilles ;

Staub, Therese ;

Greil, Richard ;

Guedj, Jeremie ;

Paiva, Jose-Artur ;

Costagliola, Dominique ;

Yazdanpanah, Yazdan ;

Burdet, Charles ;

Mentre, France .

LANCET INFECTIOUS DISEASES, 2022, 22 (02) :209-221

[2] Molecular Basis for Antiviral Action of EDP-235: A Potent and Selective SARS-CoV-2 3CLpro Inhibitor for the Treatment of Covid 19 [J].

Balakrishnan, Anand ;

Reyes, Archie ;

Shen, Ruichao ;

Bisht, Nalini ;

Sweeney, Joyce ;

Levene, Rachel ;

McAllister, Nicole ;

Cressey, Tessa ;

Manalo, Nathan ;

Rhodin, Michael H. ;

Vaine, Michael ;

Wang, Guoqiang ;

Orryan, Yat Sun ;

Goodwin, Bryan .

FASEB JOURNAL, 2022, 36

[3] Inappropriate use of ivermectin during the COVID-19 pandemic: primum non nocere! [J].

Barac, Aleksandra ;

Bartoletti, Michele ;

Azap, Ozlem ;

Bussini, Linda ;

Ergonul, Onder ;

Krause, Robert ;

Ramon Pano-Pardo, Jose ;

Power, Nicholas R. ;

Rodriguez-Bano, Jesus ;

Sibani, Marcella ;

Szabo, Balint Gergely ;

Tsiodras, Sotirios ;

Verweij, Paul E. ;

Martin Quiros, Alejandro ;

Zollner-Schwetz, Ines .

CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (07) :908-910

[4]

BARRAGRY TB, 1987, CAN VET J, V28, P512

[5]

Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI [10.1056/NEJMoa2007764, 10.1056/NEJMc2022236]

[6] Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis [J].

Berliba, Elina ;

Bogus, Maxim ;

Vanhoutte, Frederic ;

Berghmans, Pieter-Jan ;

Good, Steven S. ;

Moussa, Adel ;

Pietropaolo, Keith ;

Murphy, Robert L. ;

Zhou, Xiao-Jian ;

Sommadossi, Jean-Pierre .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (12)

[7] Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients [J].

Bernal, A. Jayk ;

da Silva, M. M. Gomes ;

Musungaie, D. B. ;

Kovalchuk, E. ;

Gonzalez, A. ;

Delos Reyes, V ;

Martin-Quiros, A. ;

Caraco, Y. ;

Williams-Diaz, A. ;

Brown, M. L. ;

Du, J. ;

Pedley, A. ;

Assaid, C. ;

Strizki, J. ;

Grobler, J. A. ;

Shamsuddin, H. H. ;

Tipping, R. ;

Wan, H. ;

Paschke, A. ;

Butterton, J. R. ;

Johnson, M. G. ;

De Anda, C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (06) :509-520

[8] TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells [J].

Bestle, Dorothea ;

Heindl, Miriam Ruth ;

Limburg, Hannah ;

Thuy Van Lam Van ;

Pilgram, Oliver ;

Moulton, Hong ;

Stein, David A. ;

Hardes, Kornelia ;

Eickmann, Markus ;

Dolnik, Olga ;

Rohde, Cornelius ;

Klenk, Hans-Dieter ;

Garten, Wolfgang ;

Steinmetzer, Torsten ;

Boettcher-Friebertshaeuser, Eva .

LIFE SCIENCE ALLIANCE, 2020, 3 (09)

[9]

Boras B, 2020, bioRxiv, DOI [10.1101/2020.09.12.293498, 10.1101/2020.09.12.293498v3, DOI 10.1101/2020.09.12.293498, 10.1101/2020.09.12.293498]

[10] Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial [J].

Bosaeed, Mohammad ;

Alharbi, Ahmad ;

Mahmoud, Ebrahim ;

Alrehily, Sanaa ;

Bahlaq, Mohannad ;

Gaifer, Zied ;

Alturkistani, Hanan ;

Alhagan, Khaled ;

Alshahrani, Saad ;

Tolbah, Ali ;

Musattat, Abrar ;

Alanazi, Maha ;

Jaha, Raniah ;

Sultana, Khizra ;

Alqahtani, Hajar ;

Al Aamer, Kholoud ;

Jaser, Saud ;

Alsaedy, Abdulrahman ;

Ahmad, Ayoub ;

Abalkhail, Mohammed ;

AlJohani, Sameera ;

Al Jeraisy, Majed ;

Almaziad, Sultan ;

Albaalharith, Nahlah ;

Alabdulkareem, Khaled ;

Alshowair, Abdulmajeed ;

Alharbi, Naif Khalaf ;

Alrabiah, Fahad ;

Alshamrani, Majid ;

Aldibasi, Omar ;

Alaskar, Ahmed .

CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (04) :602-608

← 1 2 3 4 5 6 7 8 9 →